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Abstract
Background: Rapid growth of thyroid nodules is described as being associated with thyroid cancer. The objective
of the study was to determine how the growth rate of thyroid nodules during follow-up is associated with the risk
of thyroid cancer.
Methods: Retrospective analysis of patients undergoing thyroid surgery for nodular disease and a repetitive
preoperative ultrasound work-up of at least 6 months was done. Nodule growth was considered relevant when
a volume increase >49 % was detected. Growth patterns were described as rapid for a volume increase present
over 6 to 24 months.
Results: Of the 297 analysed patients, 226 (76 %) displayed relevant nodule growth and 71 (24 %) no relevant
growth. A rapid growth pattern was seen in 73 patients (32 %). Well-differentiated thyroid cancer was diagnosed
in 33 patients (11 %; 27 papillary, 6 follicular) with a relevant nodule growth in 2 and no relevant growth in 31
patients. No rapid growth pattern was observed in any case of well-differentiated thyroid cancer. A rapid growth
pattern occurred only in benign nodules (70 patients) and in 1 patient each with a lymphoma, a metastasis of a
renal cell cancer and a metastasis of a gastric adenocarcinoma. Therapy with levothyroxine and/or iodine was
administered to 129 patients (43 %) and was significantly inversely correlated with nodule growth (odds ratio
0.27; CI 95 % 0.14–0.53, p < 0.001).
Conclusions: Thyroid nodule growth alone and especially a rapid growth pattern during follow-up for thyroid
nodular disease is not a marker for well-differentiated thyroid cancer and should not be used as a stand-alone
argument for thyroid surgery.
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Background
Thyroid nodules are frequently detected during neck
ultrasound. Their incidence is described in up to
50 % of patients, depending on age and regional iod-
ine intake [1]. Compared with this rate, the incidence
of thyroid malignancy is rare [2]. However, because of
the probability of malignancy in any thyroid nodule,
ultrasound work-up is recommended [3]. Sonographic
features suspicious for malignancy are internal calcifi-
cation, hypoechogenity, centrally increased blood flow,
infiltrative margins and a nodule taller than wider [4].
Thyroid nodule growth alone is not believed to be a
sign of malignancy, but rapid nodule growth is de-
scribed as being associated with thyroid cancer [5, 6].
The 2009 American Thyroid Association guidelines
suggest that a 50 % threshold for nodule volume in-
crease at follow-up US is a criterion for further diag-
nostic work-up to rule out malignancy [7]. Growth
occurs over time in benign thyroid nodules in 20 to
39 % of patients, depending on whether levothyroxine
and/or iodine is administered or not [8, 9]. Hence,
one is regularly confronted with this problem during
follow-up for thyroid nodules, and the definition of
substantial nodule growth remains unclear.
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Therefore, we aimed to investigate growth patterns of
thyroid nodules during preoperative work-up and their
correlation with well-differentiated thyroid malignancy.
Methods
A series of 1209 consecutive patients undergoing thyroid
resection at Tuebingen University Hospital from January
2005 to December 2013 was retrospectively analysed
using our electronic patient database. All patients with a
thyroid resection for nodular disease and a preoperative
repetitive ultrasound work-up of at least 6 months were
included in the analysis. The main outcome measure
was the correlation of nodule growth and the final histo-
pathologic diagnosis.
Patients with incomplete sonographic documentation
of the width, depth and length of the thyroid nodule as
well as complete cystic lesions were excluded. The fol-
lowing parameters were assessed: age, gender, uninodular
or multinodular thyroid, final histopathologic diagno-
sis and preoperative therapy with levothyroxine and/
or iodine. Furthermore, change in sonographic nodule
characteristics as microcalcification, hypoechogenity
and irregular nodule margins during follow-up were
recorded. Fine needle aspiration biopsy (FNAB) was
not performed routinely in the diagnostic work-up
process for thyroid nodules and thus was not further
analysed because of low availability in this series.
According to the final histopathologic examination,
underlying thyroid disease diagnosis was classified as
benign nodular thyroid disease (uninodular or multi-
nodular) and primary or secondary thyroid cancer. All
thyroid specimens were evaluated histologically by a
board-certified pathologist.
Thyroid nodule volume was retrospectively estimated
according to Brauer et al. using the maximal width, depth
and length of the nodule for calculation with the rotation
ellipsoid formula: Vellipsoidπ/6 *D length*Dwidth*Ddepth.
Only an increase in the nodule volume >49 % was inter-
preted as a relevant nodule growth, while lesser volume
changes were classified as no relevant nodule change [10].
Nodule growth pattern was further subclassified as
rapid nodule growth if the nodule volume increased
within 6 to 24 months. Data were analysed by using
statistical software, SPSS, version 21.0.0.1 (SPSS Inc.,
Chicago, IL, USA). As statistical tests, the Fisher exact
test, the chi-square test and Kruskal-Wallis test were
used where appropriate. A p value of less than 0.05 was
considered statistically significant. Multiple logistic
regression analysis was performed to investigate the in-
fluence of confounders in determining independent var-
iables for nodule growth (age, gender, type of nodularity,
levothyroxine therapy, final pathology, initial thyroid
nodule volume, follow-up duration) and for well-
differentiated thyroid cancer (age, gender, type of
nodularity, growth pattern, initial thyroid nodule vol-
ume, final thyroid nodule volume, follow-up duration,
change in sonographic characteristics). The study was
conducted in accordance with the ethical require-
ments regarding the protection of the rights and welfare
of human subjects participating in medical research
(Ethical Review Board of the University of Tuebingen,
Germany).
Results
Of 1209 patients with a thyroid resection, 368 patients
had a repetitive preoperative ultrasound work-up of at
least 6 months. A complete record of thyroid nodule di-
mensions was available in 297 (25 %) patients and was
included in the final analysis. The incidence of thyroid
malignancy in the overall population was 159 (13.2 %)
out of 1209 patients.
Of the 297 patients ultimately analysed, 226 (76 %)
displayed relevant nodule growth and 71 (24 %) no
relevant growth. A rapid nodule growth pattern
(<24 months) was seen in 73 (32 %) of the patients
with relevant nodule growth, whereas the remaining
153 patients showed moderate growth (>24 months).
Details and characteristics of patients according to
their thyroid nodule growth patterns are displayed in
Table 1. Thyroid nodule growth as sole criterion for
surgery was present in 137 (46 %) patients, while local
symptoms led to surgery in 58 patients (20 %) and suspi-
cious ultrasound features in 32 (11 %) patients.
Thyroid malignancy occurred in 37 (12.5 %) of 297
patients, 33 of whom had a well-differentiated thyroid
cancer and 4 secondary thyroid malignancies (2 with a
metastasis of a renal cell carcinoma, 1 non-Hodgkin’s
lymphoma and 1 metastasis of an adenocarcinoma of the
stomach). No case of undifferentiated or medullary thy-
roid cancer occurred in the series. In two patients with
well-differentiated thyroid cancer, lymphatic micrometas-
tases were confirmed in the central compartment, while
no gross lymphatic metastatic involvement was observed
in any patient. Twenty cases of well-differentiated thyroid
cancer were diagnosed in multinodular thyroid disease.
Twelve of these were manifested in the dominant nodule
on ultrasound, while 6 of the remaining 8 cases proved to
be incidental papillary microcarcinoma.
The initial mean nodule volume was comparable for
nodules with relevant rapid growth (2.62 ± 0.96 cm3),
with relevant moderate growth (2.3 ± 1.31 cm3) and no
growth (2.47 ± 1.29 cm3; p = 0.657). Mean volume in-
creased to 4.34 ± 1.69 cm3 for nodules with relevant
rapid growth, to 5.97 ± 3.78 cm3 for nodules with rele-
vant moderate growth and to 3.26 ± 2.65 cm3 for those
with no growth following a median follow-up period of
13 (range 6–24), 41 (range 25–79) and 24 (range 6–89)
months, respectively. Patients with relevant thyroid
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nodule growth had significantly less frequently under-
gone therapy with levothyroxine and/or iodine as
compared to patients with no relevant growth. In a
multiple logistic regression analysis, only therapy with
levothyroxine and/or iodine was significantly inversely
correlated with thyroid nodule growth (odds ratio
0.28; CI 95 % 0.142–0.539, p < 0.001).
Well-differentiated thyroid cancer occurred signifi-
cantly more often in patients with no relevant nodule
growth than in patients with relevant nodule growth. A
rapid growth pattern was not observed in any patient
with well-differentiated thyroid cancer, but in 3 patients
with secondary thyroid malignancies (1 patient each with
a lymphoma, a metastasis of a renal cell cancer and a
metastasis of a gastric adenocarcinoma), 13 with benign
uninodular disease and 57 with benign multinodular dis-
ease. Levothyroxine and/or iodine therapy was not cor-
related with nodule dignity.
Thyroid nodule characteristics according to their
histopathologic findings are displayed in Table 2.
Multivariate analysis revealed only uninodularity (odds ra-
tio 3.59; CI 95 % 1.36–9.52, p = 0.01) predictive for well-
differentiated thyroid cancer. An inverse correlation was
observed for nodule growth pattern, predicting well-
differentiated thyroid cancer (odds ratio 0.11; CI 95 %
0.05–0.23, p > 0.001). Changes in sonographic nodule
characteristics such as microcalcification, hypoechogenity
and irregular nodule margins during follow-up were ob-
served slightly more frequent in thyroid malignancies than
in benign findings, but lack significance due to their rare
appearance in multivariate analysis.
Discussion
Natural growth behaviour of thyroid nodules is contro-
versially discussed. Reports of volume change in thyroid
nodules over time vary from largely decreasing [11–13]
to predominantly increasing [8, 9], depending on factors
such as type of nodularity (uninodular vs. multinodular)
[14], iodine deficiency [15], anatomic configuration of
the nodule (cystic content) [6] and administration of
therapy with levothyroxine [16]. Most recently, Durante
et al. described a volume increase of asymptomatic and
sonographic unsuspicious nodules in only 15 % over
5 years [17]. According to our results, they found a low
incidence of thyroid cancer and no association with
nodule growth. Furthermore, there is no clear consen-
sus on how to define substantial thyroid nodule growth
[3]. Brauer et al. reported a relevant interobserver vari-
ation in thyroid nodule volume measurement when the
nodule volume change was reported to be below 50 %,
resulting in conflicting interpretations [10]. They thus
recommended that a nodule volume change of at least
49 % or more should be interpreted only as relevant
nodule shrinkage or growth [10]. Thyroid nodule
Table 1 Characteristics of the study population with followed-up thyroid nodules displaying a rapid nodule growth (increase
in nodule volume over 50 % within 24 months), moderate nodule growth (increase in nodule volume over 50 % and over
24 months) and no relevant nodule growth







No. of patients (n) 73 (%) 153 (%) 71 (24 %)
Gender (female, n) 48 (66 %)a 115 (75 %)a 46 (65 %)a 0.317
Median age at surgery, [range] 48 [19–81] 54 [16–84] 49 [17–78] 0.476
Nodularity
Uninodular 11 (15 %) 20 (13 %) 20 (28 %) 0.019
Multinodular 62 (85 %) 133 (87 %) 51 (72 %)
Median follow-up duration, months [range] 13 [6–24] 41 [25–79] 24 [6–89]
Initial mean thyroid nodule volume (cm3) 2.62 ± 0.96 2.3 ± 1.31 2.47 ± 1.29 0.598
Final mean thyroid nodule volume (cm3) 4.34 ± 1.69 5.97 ± 3.78 3.26 ± 2.65 <0.001
Benign disease (n) 70 (96 %)a 149 (97 %)a 41 (58 %)a
Malignant disease (n) 3 (%)a 4 (%)a 30 (42 %)a
Papillary thyroid cancer (>1 cm) 0 0 11
Papillary microcarcinoma (<1 cm) 0 2 14 <0.001
Follicular thyroid cancer 0 1 5
Secondary thyroid malignancy 3 1 0
Therapy with levothyroxine and/or iodinea 17 (23 %)a 66 (43 %)a 46 (65 %)a <0.023
aDisplayed as percentage of the corresponding group
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growth per se seems not to be a stand-alone marker for
malignancy. Kim et al. reported that nodules showing
more than 50 % growth during sonographic follow-up
were unlikely to result in a diagnosis of malignancy,
whereas malignancy was more often present when sus-
picious US features were found [18]. However, the re-
vised American Thyroid Association guidelines from
2015 suggested that a 50 % threshold for nodule vol-
ume increase at follow-up is a criterion for further diag-
nostic work-up and repeat FNA to rule out malignancy
(weak recommendation based on low quality evidence)
[19]. Moreover, in commonplace practice, thyroid nodules
with growth are often surgically treated to rule out cancer
[20]. The results of this study show that relevant thyroid
nodule growth over time defined as a volume increase of
more than 50 % is present in three fourths of the patients
followed. Moreover, rapid nodule growth within 24 months
was seen in 30 % of all patients. Nevertheless, nodule
growth was rarely associated with well-differentiated
thyroid cancer, and a rapid thyroid nodule growth
pattern occurred only in benign lesions, metastatic
cancers and lymphoma. All data were obtained from
a surgical database, meaning that data from patients
still under follow-up without surgery were not included in
this analysis. These results are thus not comparable to the
results of plain observational studies reporting much
lower thyroid nodule growth rates [18, 21]. In matters of
nodule growth and well-differentiated thyroid cancer, this
might even further increase the ratio of patients with rele-
vant nodule growth and without thyroid malignancy.
Also, the majority of patients in this series were op-
erated on because of relevant nodule growth without
any further signs of malignancy. Only two of these
mentioned patients subsequently displayed a papillary
microcarcinoma in thyroid nodule under surveillance
interpretable as an incidental finding without any fur-
ther clinical relevance. On the other hand, patients
with proven well-differentiated thyroid cancer showed
no substantial nodule growth. These results are com-
parable with the findings made by Ajmal et al. that
thyroid cancer is a very slow growing process that
may not progress substantially over many years [22].
Of importance, no locally infiltrating or metastatic
well-differentiated thyroid cancer was observed in the
study population, which led us to conclude that the
therapy concept was curative in all patients. Therefore,
thyroid nodule growth as a stand-alone argument for ma-
lignancy should be abandoned.
Excluding the incidental findings of papillary microcar-
cinoma, 12 of 14 well-differentiated thyroid cancers di-
agnosed in a multinodular thyroid proved to be in the
dominant nodule on ultrasound. This is in accordance
with the findings made by Kunreuther et al., who re-
ported that thyroid cancer was most often found in pa-
tients with multiple nodules in the dominant or largest
nodule [23].
In addition, changes in sonographic nodule character-
istics suspicious for malignancy during follow-up such
as microcalcification, hypoechogenity and irregular nod-
ule margins during follow-up were observed slightly
more frequently in thyroid malignancies than in benign
findings. However, these findings lacked statistical rele-
vance mainly because patients with suspicious sono-
graphic findings most likely underwent surgery initially,
the majority of patients in this study had sonographically
unsuspicious nodules in their baseline ultrasound and
Table 2 Thyroid nodule characteristics according to their histopathologic findings; p value displayed as well-differentiated thyroid
cancer vs. benign findings






N 260 27 6 33 4 37
Nodularity
Uninodular 36 (14 %) 12 1 13 (39 %) 2 15 0.001
Multinodular 224 (86 %) 15 5 20 (61 %) 2 22
Initial nodule volume >2 cm3 185 (71 %) 10 5 15 (45 %) 2 17 0.004
Nodule volume >2 cm3 at last follow-up 226 (87 %) 12 6 18 (55 %) 3 21 0.001
Median months ultrasound follow-up of nodule before surgery 28 [6–89] 31 [6–53] 11 [6–26] 0.001
Sonomorphologic change in nodule pattern
Hypoechogenity 24 (9 %) 5 1 6 (18 %) 3 9 0.237
Microcalcification 12 (4.6 %) 6 1 7 (21 %) 0 7 0.004
Taller than wide 11 (4.2 %) 3 2 5 (15 %) 2 7 0.036
Irregular nodule margins 5 (2 %) 1 0 1 (3 %) 1 2 0.553
Suppressive therapy with levothyroxine and/or iodine 109 (42 %) 17 2 19 (58 %) 1 20 0.292
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the incidence of thyroid malignancy during follow-up
was too low to show a statistically significant differ-
ence. Recent observational studies have reported that
sonographic nodule characteristics, and not nodule
growth, are important signs in the diagnosis of malig-
nancy [18].
Limitations of our findings are the facts that in
addition to a potential bias due to its retrospective de-
sign, only patients with initially mainly unsuspicious
nodules on ultrasound completed follow-up and definite
histopathologic diagnoses after surgery were included.
Three fourths of all patients operated during the study
period were excluded from the analysis because no nod-
ule follow-up was described or available. However, the
incidence of well-differentiated thyroid cancer in the
study population was comparable to that in the overall
population of patients operated during the study period,
indicating that this selection does not seem to have in-
fluenced cancer incidence.
Some reports have shown that FNAB during follow-
up of thyroid nodules, especially in cystic lesions
might have a short-term effect on nodule size and
growth pattern, making interpretation questionable
[24]. However, long-term effects of FNAB on nodule
size seem to be neglectable [25]. With regard to the
low number of preoperative FNAB and the exclusion
of complete cystic lesions, we believe that the de-
scribed alteration of nodule size due to the FNAB has
no effect on our observed general conclusion.
Since rapid thyroid nodule growth might prove to
be an undifferentiated thyroid cancer or secondary
malignancy, correct preoperative diagnosis by means
of, e.g. FNAB is of paramount importance as this
might relevantly alter the treatment in most of these
cases [26].
Conclusions
Altogether, thyroid nodule growth taken alone during
follow-up is not a marker for well-differentiated thyroid
cancer and should not be used as a stand-alone argu-
ment for thyroid surgery.
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